Updated: ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum
Why now
Thesis: ADARx pricing extends biotech IPO momentum
Catalyst to watch: First-day trading performance
Main risk: Post-IPO weakness could chill the window
Why it matters
A priced $446.3M Nasdaq debut adds to biotech IPO momentum, signaling open primary markets.
Sources
- googlenews · news.google.com · 2026-09-25 07:46 UTC